Scientific Programme

Some of these sessions have been sponsored by industry. They have had no involvement in the development of the content.

Thursday, March 20th, 2025
   Room1 Room 2
13:00 – 14:00 ILD/IPF Adherence
14:00 – 15:00 Allergy Database & Coding
15:00 – 16:00 Technologies Child Health
16:00 – 16:30 Coffee Break
16:30 – 17:30 Cost Effectiveness COPD
17:30 – 18:30 Environment, Epidemiology & Airways Biomarkers & Severe Asthma
Friday , March 21st, 2025
08:50 – 09:00 Welcome
Joan Β. Soriano, REG President
09:00 – 10:00 Inhaler Session - Propellants, planet, and the patient - the real-life impact
Chairs: Omar Usmani & Mark Levy

What does it mean to the Regulator?
Maureen Donahue Hardwick

What does it mean to the Industry?
John Bell

What does it mean to the Clinician?
Toby Capstick
10:00 – 10:30 ILD/IPF Session
Chair: Pilar Rivera Ortega  

Time taken from primary care referral to a specialist centre diagnosis of idiopathic pulmonary fibrosis: An opportunity to improve patient outcomes?
Mark Jones
10:30 – 10:45 Coffee Break
10:45 – 11:30 Readers', authors', and editors' perspectives on observational research
Chairs:  Nicolas Roche & Therese Lapperre

How to lie with statistics to a chest physician
Joan Β. Soriano

An Editor’s perspective on observational research
David Price
11:30 – 12:30 Early Career Travel Grant Winners Oral Presentation
Chair: Dermot Ryan
12:30 – 13:30 Lunch Break & Poster viewing
13:30 – 15:00 COPD Session
Chairs: Bernardino Alcazar Navarrete & Frits M.E. Franssen
 
Predicting the risk for first COPD severe exacerbation
Bernardino Alcazar Navarrete

Triple therapy and very severe COPD: Rational for a REG study
Chin Kook Rhee

New Drugs in COPD: Will they make a real-life difference?
Nicolas Roche
15:00 – 15:30 Coffee Break
15:30 – 16:25

United Airways Disease session
Chairs: Piotr Kuna & Stefania Gallo

Novel treatments in Allergic Rhinitis
Walter G. Canonica

Rhinitis +/- asthma: different diseases?

Ralph Mosges

(R)evolution of care in CRSwNP
Peter Hellings

16:25 – 17:10 AI/Digital in Respiratory Diseases session
Chairs: Job van Boven & Fulvio Braido

Can interactions with AIs provide patient support?
Alan Kaplan

Can digital adherence support prevent disease progression?

Amy Chan
17:10 – 17:55 PRO/CON – Vaccines
Chair: Joan Β. Soriano

Pneumococcal vaccine is the most important respiratory vaccine for our high-risk patients to receive
PRO: Filipe Froes

RSV is the most important respiratory vaccine for our high-risk patients to receive
CON: Alan Kaplan

Vote & Summary Discussion
Joan Β. Soriano
Saturday, March 22nd, 2025
09:00 – 10:00 Asthma Session - Expansion of biologic use in asthma: Where to?
Chairs: Nikos Papadopoulos & Jennifer Quint

Younger age
Adnan Custovic

Milder disease
Enrico Marco Heffler

Multimorbidities
Désirée Larenas-Linnemann
10:00 – 10:45 Bronchiectasis Session
Chair: Nicolas Roche

Current and future perspectives in the treatment of bronchiectasis

Eva Van Braeckel
10:45 – 11:00 Coffee Break
11:00 – 12:35 Improving severe asthma care - ISAR’s research and quality improvement highlights
Chairs: David Price & Veronica Mendez

Exploring definitions and predictors of severe asthma remission post-biologic (FULL BEAM II)
Luis Perez-de-Llano & Ghislaine Scelo

What comes next for research on severe asthma remission? (GLEAM and SPOTLIGHT)
Walter G. Canonica &  Victoria Carter

Practice change in severe asthma - where are we now in terms of standardizing care and data management  
Désirée Larenas-Linnemann & Celine Goh

Impact of biologics on new onset of OCS-related outcomes in severe asthma (SOLAR II)
David Price & Piotr Kuna

Eliminating long-term OCS and frequent intermittent OCS
Pujan Patel & Freya Tyrer

Modelling the health system impact of earlier intervention in severe asthma
Soram Patel & Alison Evans
12:35 – 13:50 Integrating RWE into Guidelines session  
Chairs: Walter G. Canonica & Maria Jose Torres

The need for RWE to be included in guidelines
Stefano Del Giacco

The GRADE system to integrate RWE
Holger Schunemann

Real-Life experience of guideline creation
Nicolas Roche

Discussion  
13:50 Meeting Close